PAUL R ANDERSON
Engineering in Belmont, MA
License number
Massachusetts 39759
Issued Date
Mar 21, 1997
Expiration Date
Jun 30, 1998
Type
Civil Engineer
Address
Address
Belmont, MA 02478
Professional information
Neuroprotective Molecules And Methods Of Treating Neurological Disorders And Inducing Stress Granules
US Patent:
2013019, Aug 1, 2013
Filed:
Jul 8, 2011
Appl. No.:
13/808863
Inventors:
Paul Anderson - Belmont MA, US
Pavel Ivanov - Brighton MA, US
Mohammed Emara - Newton MA, US
Pavel Ivanov - Brighton MA, US
Mohammed Emara - Newton MA, US
Assignee:
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA
International Classification:
C07H 21/02
US Classification:
514 44 R, 536 245, 435375
Abstract:
Provided herein are neuroprotective molecules containing a sequence of 25-35 contiguous nucleotides that is at least 80% identical to a contiguous sequence between nucleotide 1 and nucleotide 50 of a mature human tRNA and at least four contiguous guanosine-containing nucleotides, where the sequence of 25-35 contiguous nucleotides contains a D-loop stem structure, the at least four contiguous guanosine-containing nucleotides are located at the 5′ end of the neuroprotective molecule, and the neuroprotective molecule contains at least one deoxyribonucleotide. Also provided are molecules containing a sequence of 25-35 contiguous nucleotides that is at least 80% identical to a contiguous sequence between nucleotide 1 and nucleotide 50 of a mature human tRNA selected from the group of tRA, tRNA, tRNA, tRNA, tRNA, tRNA, tRN, tRNA, tRNA, tRNA, tRNA, tRNA, tRNA, tRNA, tRNA, tRNA, tRNA, tRNA, tRNA, and tRNA; and at least four contiguous guanosine-containing nucleotides, where the sequence of 25-35 contiguous nucleotides contains a D-loop stem structure and the at least four contiguous guanosine-containing nucleotides are located at the 5′ end of the neuroprotective molecule. Also provided are methods of inducing or increasing stress granule formation in a cell, decreasing protein translation in a cell, decrease stress-induced cell death, or treating a neurological disorder associated with neuron death in a subject using at least one of these neuroprotective molecules or a C-myeoligonucleotide. Also provided are methods of identifying a candidate translation inhibitory nucleic acid.
Tia-1 Binding Proteins And Isolated Complementary Dna Encoding The Same
US Patent:
5798245, Aug 25, 1998
Filed:
Oct 6, 1994
Appl. No.:
8/318947
Inventors:
Paul J. Anderson - Belmont MA
Qingsheng Tian - Cambridge MA
Qingsheng Tian - Cambridge MA
Assignee:
Dana-Farber Cancer Institute - Boston MA
International Classification:
C12N 912, C12N 900, C07K 1446
US Classification:
435194
Abstract:
Complementary DNA (cDNA) has been isolated having a sequence that encodes a polypeptide that binds TIA-1 in a double transformation. In one embodiment, the polypeptide is immunologically reactive with the monoclonal antibody produced by the hybridoma designated ATCC #HB-11721. Specific cDNA sequences have been determined and amino acid sequences have been deduced therefrom.
Natural Killer Cell-Specific Antigen And Antibodies That Identify The Same
US Patent:
5786160, Jul 28, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/484748
Inventors:
Paul Anderson - Belmont MA
Eric Vivier - Marseilles, FR
Eric Vivier - Marseilles, FR
Assignee:
Dana-Farber Cancer Institute - Boston MA
International Classification:
A61K 33395, C07K 1628, G01N 33579
US Classification:
435 724
Abstract:
A novel natural killer cell-specific molecule, designated as PEN5, consisting essentially of a glycoprotein pair called PEN5. alpha. and PEN5. beta. , having apparent molecular weights of 120-150 and 210-245 kdal, respectively. Monoclonal antibodies, including immunoreactive fragments and derivatives thereof, that bind to unique epitopes present on this NK cell-specific molecule; hybridomas that produce the monoclonal antibodies; methods of using the antibodies and fragments and derivatives; and methods for detecting and/or removing natural killer cells from a sample containing a mixed population of cells are also provided.
Rna-Induced Translational Silencing And Cellular Apoptosis
US Patent:
8173616, May 8, 2012
Filed:
May 1, 2009
Appl. No.:
12/990493
Inventors:
Paul Anderson - Belmont MA, US
Satoshi Yamasaki - Brookline MA, US
Satoshi Yamasaki - Brookline MA, US
Assignee:
The Brigham and Women's Hospital, Inc. - Boston MA
International Classification:
A61K 31/70, C07H 21/02, C07H 21/04
US Classification:
514 44A, 536 241, 536 245
Abstract:
The invention is directed to RNA molecules that can be used to inhibit protein synthesis and to induce cells to undergo apoptosis. It also includes pharmaceutical compositions containing the RNAs that can be used in treating or preventing tumors; abnormal dermatological growths and viral infections.
Tia-1 Binding Proteins And Isolated Complementary Dna Encoding The Same
US Patent:
5948656, Sep 7, 1999
Filed:
Feb 4, 1997
Appl. No.:
8/795303
Inventors:
Paul J. Anderson - Belmont MA
Qingsheng Tian - Cambridge MA
Qingsheng Tian - Cambridge MA
Assignee:
Dana-Farber Cancer Institute - Boston MA
International Classification:
C12N 900, C12N 912, C12N 121, C07H 2104
US Classification:
435183
Abstract:
Complementary DNA (cDNA) has been isolated having a sequence that encodes a polypeptide that binds TIA-1 in a double transformation. In one embodiment, the polypeptide is immunologically reactive with the monoclonal antibody produced by the hybridoma designated ATCC #HB-11721. Specific cDNA sequences have been determined and amino acid sequences have been deduced therefrom.
Trangenic Mice With A Disruption In The Tiar Gene
US Patent:
6180849, Jan 30, 2001
Filed:
Mar 17, 1998
Appl. No.:
9/039999
Inventors:
Michel Streuli - Brookline MA
Paul Anderson - Belmont MA
Andreas Beck - Lucerne, CH
Paul Anderson - Belmont MA
Andreas Beck - Lucerne, CH
Assignee:
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12N 1585, C12N 1586, G01N 3300, A01K 6700
US Classification:
800 18
Abstract:
The invention features transgenic non-human mammals containing a mutation in one or both alleles of the endogenous TIAR gene, and cell lines derived from some of these mammals. The mammals and cell lines of the invention can be employed to identify compounds useful in treating infertility, obesity, neurological disorders, and ovarian sex cord stromal tumors.
Natural Killer Cell-Specific Antigen And Antibodies That Identify The Same
US Patent:
6194549, Feb 27, 2001
Filed:
Jul 28, 1998
Appl. No.:
9/123446
Inventors:
Paul Anderson - Belmont MA
Eric Vivier - Marseille, FR
Eric Vivier - Marseille, FR
Assignee:
Dana-Farber Cancer Institute - Boston MA
International Classification:
C07K 14705
US Classification:
530350
Abstract:
A novel natural killer cell-specific molecule, designated as PEN5, consisting essentially of a glycoprotein pair called PEN5. alpha. and PEN5. beta. , having apparent molecular weights of 120-150 and 210-245 kdal, respectively. Monoclonal antibodies, including immunoreactive fragments and derivatives thereof, that bind to unique epitopes present on this NK, cell-specific molecule; hybridomas that produce the monoclonal antibodies; methods of using the antibodies and fragments and derivatives; and methods for detecting and/or removing natural killer cells from a sample containing a mixed population of cells are also provided.